Establishment Labs (NASDAQ:ESTA) Price Target Raised to $90.00 at Mizuho

Establishment Labs (NASDAQ:ESTA) had its target price raised by research analysts at Mizuho from $85.00 to $90.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price objective indicates a potential upside of 21.38% from the company’s current price.

A number of other equities research analysts have also weighed in on ESTA. Wall Street Zen raised Establishment Labs from a “sell” rating to a “hold” rating in a research note on Sunday, October 19th. Citigroup lifted their price target on Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. boosted their price objective on Establishment Labs from $45.00 to $71.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. BTIG Research raised their target price on shares of Establishment Labs from $70.00 to $81.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Establishment Labs Price Performance

Shares of Establishment Labs stock opened at $74.15 on Wednesday. The company has a debt-to-equity ratio of 15.06, a quick ratio of 2.10 and a current ratio of 3.33. Establishment Labs has a 52-week low of $26.56 and a 52-week high of $74.35. The company has a fifty day moving average of $59.72 and a 200-day moving average of $47.10. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -26.11 and a beta of 1.01.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.16. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 235.45%. The business had revenue of $53.78 million during the quarter, compared to the consensus estimate of $52.28 million. During the same period in the previous year, the firm posted ($0.59) earnings per share. The firm’s revenue for the quarter was up 33.8% on a year-over-year basis. Equities research analysts expect that Establishment Labs will post -2.41 EPS for the current year.

Hedge Funds Weigh In On Establishment Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in ESTA. NewEdge Advisors LLC boosted its holdings in Establishment Labs by 3,702.4% in the third quarter. NewEdge Advisors LLC now owns 9,468 shares of the company’s stock valued at $388,000 after acquiring an additional 9,219 shares in the last quarter. PharVision Advisers LLC bought a new position in Establishment Labs in the 3rd quarter worth $203,000. Voleon Capital Management LP bought a new position in Establishment Labs in the 3rd quarter worth $1,287,000. Vestal Point Capital LP purchased a new stake in shares of Establishment Labs in the 3rd quarter worth about $4,099,000. Finally, Strategic Wealth Partners Ltd. lifted its position in shares of Establishment Labs by 63.7% in the 3rd quarter. Strategic Wealth Partners Ltd. now owns 71,807 shares of the company’s stock worth $2,943,000 after purchasing an additional 27,931 shares during the period. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.